Cystic Fibrosis Canada publishes recommendations for the follow-up of pregnancies and newborns of mothers who are receiving cystic fibrosis modulator therapies
TORONTO (June 28, 2023) – Cystic Fibrosis Canada’s Healthcare Advisory Council has published recommendations for the follow-up of pregnancies and newborns of mothers who are receiving cystic fibrosis transmembrane conductance regulator (CFTR) modulators, like Trikafta.
“We are pleased to share our newest Canadian recommendations on the use of modulator therapies for people who are pregnant and newborns of mothers taking CFTR modulators,” said Jana Kocourek, Program Director, Healthcare at Cystic Fibrosis Canada. “This is an exciting update and an example of the tremendous progress that has been made in the treatment of cystic fibrosis.”
The recommendations are intended for use by care teams and were developed by CF experts at the cystic fibrosis pediatric clinic at du Centre Mère-Enfant du CHU de Québec-Université Laval, reviewed by the Canadian CF Newborn screening group and endorsed by Cystic Fibrosis Canada’s Healthcare Advisory Council (HAC).
Cystic Fibrosis Canada’s HAC recently led the development of the Guidelines for Diagnosis and Treatment of Pulmonary Exacerbations in Patients with Cystic Fibrosis, Aerosolized Antibiotic Use in Cystic Fibrosis, Antibiotic Dosing Guideline for Cystic Fibrosis and most notably the Guideline for CFTR Modulator Therapies for Patients with Cystic Fibrosis, which helped to facilitate the rollout of Trikafta in our community. Our HAC will continue to develop guidelines for other topics related to CF care.
View the recommendations for the follow-up of pregnancies and mothers of newborns who are receiving cystic fibrosis transmembrane conductance regulator (CFTR) modulators here.
